Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 1:25 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–18 of 18 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: CC-220 2 mg Clear all

Conditions: Healthy Volunteers
Interventions: CC-220; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Multiple Myeloma, Refractory Multiple Myeloma, Relapsed Multiple Myeloma
Interventions: Talquetamab, Iberdomide, Dexamethasone, Bone Marrow Biopsy; Biological · Drug · Procedure
Lead sponsor: Alfred Chung, MD; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Pharmacokinetics
Interventions: CC-220, Rifampin, Itraconazole; Drug
Lead sponsor: Celgene Corporation; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Multiple Myeloma
Interventions: Iberdomide, Daratumumab, Dexamethasone, Carfilzomib; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 4
States / cities: Birmingham, Alabama • Columbus, Ohio • Portland, Oregon + 1 more

Conditions: Multiple Myeloma
Interventions: Dexamethasone, Daratumumab, Bortezomib, Iberdomide; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 939 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2032
U.S. locations: 43
States / cities: Hot Springs, Arkansas • Cerritos, California • Fountain Valley, California + 38 more

Conditions: Multiple Myeloma
Interventions: Iberdomide, Daratumumab/rHuPH20 Co-formulation; Drug
Lead sponsor: Barbara Ann Karmanos Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 2
States / cities: Detroit, Michigan • Lansing, Michigan

Conditions: Lymphoma
Interventions: CC-220, Rituximab, Obinutuzumab; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 6
States / cities: Phoenix, Arizona • Lake Mary, Florida • Rochester, Minnesota + 3 more

Conditions: Systemic Lupus Erythematosus
Interventions: CC-220, Placebo; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 35
States / cities: Birmingham, Alabama • Paradise Valley, Arizona • Tucson, Arizona + 30 more

Conditions: Lupus Erythematosus, Systemic
Interventions: CC-220, Placebo; Drug · Other
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 289 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 46
States / cities: Tuscaloosa, Alabama • Mesa, Arizona • Fullerton, California + 36 more

Conditions: Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular
Interventions: JCAR017, Durvalumab, CC-122, Ibrutinib, CC-220, Relatlimab, Nivolumab, CC-99282; Biological · Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 9
States / cities: Duarte, California • Atlanta, Georgia • Chicago, Illinois + 5 more

Conditions: Newly Diagnosed Multiple Myeloma
Interventions: Isatuximab, Iberdomide, Bortezomib, Dexamethesone; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2034
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Lymphoma, B-Cell
Interventions: CC-220, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, CC-99282, Polatuzumab vedotin; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 15
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Duarte, California + 12 more

Conditions: Lymphoma, B-Cell
Interventions: CC-220, Polatuzumab vedotin, Rituximab, Tafasitamab, Gemcitabine, Cisplatin, Dexamethasone, Bendamustine, Lenalidomide; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 3
States / cities: Boston, Massachusetts • Ann Arbor, Michigan • Sioux Falls, South Dakota

Conditions: Myeloma, Multiple Myeloma, Refractory Multiple Myeloma
Interventions: Elotuzumab, Iberdomide, Dexamethasone; Drug
Lead sponsor: Omar Nadeem, MD; Other
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2034
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Multiple Myeloma
Interventions: Carfilzomib, Iberdomide, Oral Dexamethasone; Drug
Lead sponsor: Hackensack Meridian Health; Other
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Hackensack, New Jersey

Conditions: Multiple Myeloma
Interventions: Iberdomide, Elotuzumab, Dexamethasone; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Multiple Myeloma
Interventions: CC-220, Dexamethasone, Daratumumab, Bortezomib, Carfilzomib, Daratumumab - 16mg/kg, Bortezomib (BTZ), Daratumumab- 1800mg; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 466 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2028
U.S. locations: 58
States / cities: Scottsdale, Arizona • Little Rock, Arkansas • Atlanta, Georgia + 24 more

Conditions: Healthy
Interventions: CC-220 0.03 mg, CC-220 0.1 mg, CC-220 0.3 mg, CC-220 1 mg, CC-220 2 mg, Placebo, CC-220; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Madison, Wisconsin

Search by objective public record fields.

A Study to Assess the Relative Bioavailability of a New CC-220 Capsule Formulation, Compared to a Reference CC-220 Capsule Formulation, in Healthy Adult Subjects

Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma

Study to Evaluate the Effect of Cytochrome P450 (CYP) 3A Inhibition and Induction on the Pharmacokinetics of CC-220 in Healthy Subjects

COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide

Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Iberdomide and Daratumumab as Maintenance Therapy After an Autologous Stem Cell Transplant for Multiple Myeloma

A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas

A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.

A Study to Evaluate the Efficacy and Safety of CC-220 in Subjects With Active Systemic Lupus Erythematosus

A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies

Isatuximab, Iberdomide, Bortezomib, Dexamethasone in Transplant Ineligible/Deferred Newly Diagnosed Myeloma

Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma

Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma

Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM

Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple Myeloma

A Study of Iberdomide (CC-220) in Combination With Elotuzumab and Dexamethasone for Relapsed/Refractory Multiple Myeloma

A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma

2-part Study to Assess Safety, Pharmacokinetics & Pharmacodynamics of CC-220 & Effect of Food on CC-220 in Healthy Subjects